Product nameMouse Complement C3 ELISA Kit
See all C3 kits
Intra-assay Sample n Mean SD CV% Overall < 10% Inter-assay Sample n Mean SD CV% Overall < 10%
Sample typeSerum, Plasma
Assay typeSandwich (quantitative)
Range3.13 ng/ml - 200 ng/ml
> 85 %
Sample specific recovery Sample type Average % Range Serum > 85 % - %
Assay durationMultiple steps standard assay
Species reactivityReacts with: Mouse
Predicted to work with: Rat
Mouse Complement C3 ELISA kit is a highly sensitive two-site enzyme linked immunoassay (ELISA) for measuring Complement C3 in mouse biological samples.
In this assay the Complement C3 present in samples reacts with the anti- Complement C3 antibodies which have been adsorbed to the surface of polystyrene microtitre wells. After the removal of unbound proteins by washing, anti- Complement C3 antibodies conjugated with horseradish peroxidase (HRP), are added. These enzyme-labeled antibodies form complexes with the previously bound Complement C3. Following another washing step, the enzyme bound to the immunosorbent is assayed by the addition of a chromogenic substrate, 3,3’,5,5’-tetramethylbenzidine (TMB). The quantity of bound enzyme varies directly with the concentration of Complement C3 in the sample tested; thus, the absorbance, at 450 nm, is a measure of the concentration of Complement C3 in the test sample. The quantity of Complement C3 in the test sample can be interpolated from the standard curve constructed from the standards, and corrected for sample dilution.
Tested applicationsSuitable for: Sandwich ELISAmore details
Storage instructionsStore at +4°C. Please refer to protocols.
Components 1 x 96 tests 100X HRP-conjugated anti-mouse Complement C3 antibody 1 x 150µl 20X Wash Buffer Concentrate 1 x 50ml 5X Diluent Concentrate 1 x 50ml Chromogen Substrate Solution 1 x 12ml Mouse Complement C3 Calibrator (lyophilized) 1 vial Mouse Complement C3 ELISA Microplate 1 unit Stop Solution 1 x 12ml
FunctionC3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
Acylation stimulating protein (ASP): adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for GPR77. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of GPR77.
Tissue specificityPlasma. The acylation stimulating protein (ASP) is expressed in adiopocytes and released into the plasma during both the fasting and postprandial periods.
Involvement in diseaseDefects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:613779]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
Note=Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage.
Sequence similaritiesContains 1 anaphylatoxin-like domain.
Contains 1 NTR domain.
modificationsC3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g. C3a is further processed by carboxypeptidases to release the C-terminal arginine residue generating the acylation stimulating protein (ASP). Levels of ASP are increased in adipocytes in the postprandial period and by insulin and dietary chylomicrons.
Phosphorylation sites are present in the extracellular medium.
- Information by UniProt
- Acylation stimulating protein cleavage product
Our Abpromise guarantee covers the use of ab157711 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Sandwich ELISA||Use at an assay dependent concentration.|
Complement C3 measured in tissue extracts (total protein concentration: Ms liver - 17.46 mg/mL, Ms kidney - 15.6 mg/mL; prepared in RIPA buffer with protease inhibitor) and cell culture supernatants showing quantity (ng) per mL of tested sample. Tissue samples were diluted 100-10000 fold. Supernatants were diluted 1-10 fold.
Complement C3 measured in biological fluids of healthy species showing quantity (ng) per mL of tested sample. Samples were diluted 8000-128000 fold.
Representative standard curve using ab157711 Complement C3 Mouse ELISA kit
This product has been referenced in:
- Huang X et al. VSIG4 mediates transcriptional inhibition of Nlrp3 and Il-1ß in macrophages. Sci Adv 5:eaau7426 (2019). Read more (PubMed: 30662948) »
- Kim TH et al. Anti-Bacterial Effect of CpG-DNA Involves Enhancement of the Complement Systems. Int J Mol Sci 20:N/A (2019). Read more (PubMed: 31295956) »